The NeurologyLive® Parkinson disease Disease Spotlight page gives readers key updates and detailed coverage on the most recent expert conversations and data presentations relevant to the treatment of the movement disorder.
Levodopa-Entacapone-Carbidopa Intestinal Gel Shows Minimal Benefits Over Traditional Parkinson Therapies
Apart from the small pump system, which was preferred by the patients, the study found no clear advantage of levodopa-entacapone-carbidopa to levodopa-carbidopa intestinal gel.
Remote Palliative Care Intervention Yields Positive Outcomes in Parkinson Disease and Related Disorders
A recent study suggests that palliative education and telehealth improve quality of life and advance care planning among patients with Parkinson disease and related disorders.
Newly Announced VISION Study Aims to Improve Parkinson DBS Localization Through SIS Brain Visualization Software
If successful, the study has potential implications for future surgical outcomes and patient experience among those with Parkinson disease.
Improving Access to Care in Parkinson Disease: Expanding Objective Diagnostics and Telemedicine
Standardizing protocols and incorporating objective diagnostics and telemedicine can enhance care for patients with PD and alleviate the burden on healthcare systems.
Patient Dosing Commenced in Phase 2 ASCEND Study of Parkinson Agent CVN424
The trial will feature 60 individuals with early-stage Parkinson disease who will be randomly assigned 1:1 to either daily CVN424 or placebo for a 12-week treatment period.
Carbidopa Levodopa Enteral Suspension Leads to Greater Cost-Effectiveness Over Standard Care
Carbidopa levodopa enteral suspension for Parkinson disease demonstrated cost-effectiveness compared to standard care, with an incremental cost-effectiveness ratio of $7711/QALY in a real-world study.
NeurologyLive® Brain Games: November 12, 2023
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Parkinson disease.
Motor Evoked Potentials of Parkinson Disease Increased Through Accelerated Transcranial Ultrasound Neuromodulation, Pilot Study Shows
In a small-scale trial, patients with Parkinson disease on accelerated theta-burst transcranial ultrasound demonstrated higher motor evoked potentials than those on sham, with no statistically significant changes in MDS-UPDRS-III scores.
Extracellular Vesicles Prove Potential Value as α-Synuclein Biomarker in Parkinson Disease
The data suggest that central nervous system-derived extracellular vesicles in the blood will likely play a key role in biomarker development, especially for patients with Parkinson disease, in the coming years.
First-In-Human Trial of Nurr1 Activator HL192 in Parkinson Disease Initiated
In animal models, HL192 showed disease-modifying effects, as demonstrated through improvements in behavioral deficits.
Parkinson Disease Risk Increased Through Football
Among football players, odds of having a parkinsonism or Parkinson disease diagnosis were greater with more seasons and higher level of football play.
Patient-Reported Outcome Measure PRO-PD Reliable for Monitoring Symptoms of Parkinson Disease
PRO-PD showed good 6-month test-retest reliability, as well as good convergent validity between other widely used validated scales of PD.
Combining Rasagiline With Levodopa and Benserazide Hydrochloride Shows Positive Therapeutic Effects in Mid-Late Parkinson Disease
During the progression of the movement disorder, older patients with Parkinson disease may see changes in their insulin-like growth factor and serum homocysteine indices but a potential therapy could improve these factors.
Incorporating Augmented Reality to Treat Parkinson Disease Gait Problems
Jay Alberts, PhD, the Edward F. and Barbara A. Bell Endowed Chair at Cleveland Clinic, provided comment on a recently published randomized controlled trial assessing the therapeutic potential of an augmented reality program for postural instability and gait dysfunction in Parkinson disease.
NDA Resubmitted for Supernus’ Apomorphine Infusion Device SPN-830
After Supernus met with the FDA earlier this year, the company believes it has addressed the agency’s requests mentioned in its complete response letter delivered in October 2022.
Improving Care Access and Utilization for Parkinson Disease: James Beck, PhD
The senior vice president and chief scientific officer of the Parkinson’s Foundation discussed a recently published Medicare claims analysis that highlighted significant issues with access to proper care for patients with Parkinson disease. [WATCH TIME: 4 minutes]
The Effects of Depression in Parkinson Disease and Need for Mental Health Professionals: James Beck, PhD
The senior vice president and chief scientific officer of the Parkinson’s Foundation provided perspective on the reasons for the lack of mental health specialists in Parkinson disease care and the complexities behind treating depression. [WATCH TIME: 4 minutes]
Adjusting Motor Fluctuation Management in an Era of Neuromodulation: Laxman Bahroo, DO
The professor of neurology and resident program director at MedStar Georgetown University Hospital discussed how Parkinson disease motor fluctuations are managed amid new, novel technologies incorporated in the field. [WATCH TIME: 4 minutes]
Standard and Nonstandard Physical Therapy Show Similar Effectiveness for Parkinson Disease
Although research supports the use of physical therapy as an effective treatment for Parkinson disease, implementation factors including type, timing, frequency, and durability of outcomes remain mainly untouched.
Role of Gut Microbiome, Alpha Synuclein in the Prodromal Stage of Parkinson Disease
Virginia Gao, MD, PhD, a movement disorders fellow at Weill Cornell Medicine, discussed several topics related to the use of biomarkers in the prodromal stages of neurodegenerative disorders like Parkinson disease.
CUE1 Device, a Vibrational Therapy to Potentially Treat Parkinson Disease Symptoms: Alistair Mackett, MD
The movement disorder specialist at Cambridge University Hospitals NHS Foundation Trust talked about a patient with treatment-resistant Parkinson disease who experienced significant improvement in motor symptoms after using a vibrational therapy. [WATCH TIME: 8 minutes]
Positive Phase 1 Data on Gut-Targeting Therapy in Neurodegenerative Diseases Announced
Because its gut-acting and gut-restricted, the safety profile of DGX-001 was considered advantageous in comparison to traditional neuropsychiatric therapies.
Episode 93: Caring for Women With Parkinson Disease
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jill Farmer, DO, MPH. [LISTEN TIME: 28 minutes]
FDA Approves Image Guided Programming Software for Vercise Deep Brain Stimulation Systems
The fourth-generation deep brain stimulation system is designed to treat the symptoms of Parkinson disease and essential tremor by delivering targeted electrical stimulation via surgically-implanted leads in the brain connected to an implantable pulse generators.
The Changing Landscape of Parkinson Disease and New Therapies on the Horizon: Mazen Elkurd, DO
The director of the Movement Disorders Center at Baylor University Medical Center in Dallas, a part of Baylor Scott & White Health, talked about the evolution of treatment for Parkinson disease and the new promising therapies patients may seen over the coming years. [WATCH TIME: 3 minutes]
FDA Issues Complete Response Letter to Amneal for Parkinson Agent IPX203
Reasons behind the CRL were not related to efficacy and do not impact Amneal’s 2023 financial guidance, which did not include IPX203 revenues.
UB-312 Meets Primary Objectives in Phase 1 Trial for Parkinson Disease
In patients with early Parkinson disease, results showed that UB-312 was generally safe and well-tolerated, which supports the advancement of the vaccine into further clinical development.
The Impact of Social Participation on Cognitive Function in Patients With Parkinson Disease: Ling Wan-Albert, OTD, OTR/L
The assistant professor of occupational therapy at the New York Institute of Technology talked about educating patients with Parkinson disease about the importance of maintaining social participation for cognitive function at ATMRD 2023. [WATCH TIME: 5 minutes]
Emerging Therapies in Movement Disorders and Chronic Care Management for Parkinson Disease: Safia Abdillahi, ACNP-BC, DNP
The nurse practitioner in the movement disorder division at Georgetown University Hospital discussed differences in available therapies for movement disorders versus multiple sclerosis and using a chronic care management model in Parkinson disease. [WATCH TIME: 5 minutes]
Contraindicated Medication Use Significantly Impacts Length of Hospitalization in Parkinson Disease
Patients with Parkinson disease who were inpatients had significant impacts on their length of stay, readmissions, and morbidity after hospitalization when administered contraindicated medications.
The Rising Prevalence and Behavioral Implications of Dementia in Parkinson Disease: Nahid Mohammadzadeh, MD
At AMTRD 2023, the graduate research assistant at Brown University talked about the prevalence of rapidly progressive dementia and cognition fluctuation in Parkinson disease as well as the effects of treatments for the condition. [WATCH TIME: 5 minutes]
Filling a Therapeutic Need in Parkinson Disease: Flexibility With IPX203
Robert A. Hauser, MD, MBA, director of the Parkinson’s and Movement Disorders Center at the University of South Florida, provided insight on the therapeutic potential of IPX203, and why it adds flexibility to the treatment of Parkinson disease.
A Multifaceted Approach to Understanding ON and OFF Periods in Parkinson Disease: Salima Brillman, MD
At AMTRD 2023, the movement disorder neurologist at the Parkinson’s Disease and Movement Disorder Center of Silicon Valley talked about the current care landscape for Parkinson disease and improving on-time for patients experiencing OFF periods. [WATCH TIME: 5 minutes]
Advanced Practice Providers Recognize and Consider the Impact of On-Demand Therapy in Parkinson Disease
In a recent survey, a group of advanced practice providers recognized the importance and considered the emotional impact of the unexpected return of symptoms on the life of a patient with Parkinson disease.
Extended-Release Amantadine Offers More Predictable Good ON Time for Those With Parkinson Disease
Pooled results of a post hoc analysis from phase 3 studies of amantadine (Gocovri; Supernus) suggest that the therapy offers increased good ON time, and in intervals that are more predictable for patients, compared with placebo.
Samelisant Shows Potential as a Treatment for Excessive Daytime Sleepiness in Parkinson Disease
Preclinical findings show the potential of samelisant, a potent and orally active Histamine H3 receptor inverse agonist, as a potential treatment for patients with Parkinson disease who experience excessive daytime sleepiness.
Biogen and Denali Terminate Phase 3 LIGHTHOUSE Study of BIIB122 in LRRK2-related Parkinson Disease
The companies have noted that the decision was not made because of safety or efficacy data, but to refocus efforts on the ongoing phase 2b LUMA trial of BIIB122.
Trichloroethylene Exposure and Usage, Environmental Associations in Parkinson Disease: Samuel M. Goldman, MD, MPH
The clinical professor in the department of neurology at the University of California, San Francisco, emphasized the need to restrict trichloroethylene availability and the challenges in studying environmental factors associated with Parkinson disease. [WATCH TIME: 4 minutes]
Environmental Exposures and the Impact of Trichloroethylene on Parkinson Disease: Samuel M. Goldman, MD, MPH
The clinical professor in the Department of Neurology at the University of California, San Francisco, talked about the association between contaminated water and Parkinson disease. [WATCH TIME: 6 minutes]
Future of Treating Parkinson Disease Psychosis, Overcoming Challenges in Clinical Trials: Aaron Ritter, MD
The director of the Memory & Cognitive Disorders Clinic at Hoag Neuroscience Institute provided perspective on the difficulties with testing agents for Parkinson disease psychosis, and the future outlook of treating the symptom. [WATCH TIME: 4 minutes]
Digital Health Assessments May Improve Parkinson Disease Diagnosis
Study shows that digital devices can provide objective and real-world measures of Parkinson disease, capturing key motor and nonmotor features of for early diagnosis of the neurodegenerative disorder.
Significant Impact of Carbidopa Levodopa Agent ND0162 in Parkinson Disease
The director of the James J. and Joan A. Gardner Family Center discussed data from the phase 3 BouNDlesstrial assessing a continuous, subcutaneous levodopa/carbidopa delivery system for patients with Parkinson disease experiencing motor fluctuations. [WATCH TIME: 3 minutes]
Taking a Symptom-Based Approach to Parkinson Disease Psychosis: Aaron Ritter, MD
The director of the Memory & Cognitive Disorders Clinic at Hoag Neuroscience Institute discussed the future of treating Parkinson disease psychosis, and potential ways to lower risk of poor long-term outcomes. [WATCH TIME: 3 minutes]
Contaminated Drinking Water, Environmental Factors May Increase Risk of Parkinson Disease
A recent published study highlighted the importance of environmental risk factors for Parkinson disease, such as exposure to trichloroethylene and other volatile organic compounds.
Understanding the NLRP3 PET Tracer and Its Potential Impact on Parkinson Disease Treatment
Marcelo Bigal, MD, PhD, chief executive officer of Ventus Therapeutics, talked about the relationship between inflammation and neurodegeneration in Parkinson disease, and the importance of targeting NLRP3.
Cultural Differences Impact Subjective Experience of Dyskinesias in Parkinson Disease
Differences in personal experience of dyskinesias in Parkinson disease were observed across multiple cultures, which could be attributable to intrinsic cultural peculiarities.
Benefits of Boxing and Exercise for Patients With Parkinson Disease
Timothy A. Leichliter, MD, a neurologist at Allegheny Health Network, provided context on the institution’s boxing program for Parkinson disease, and the need for patients to remain active.
Elevated Risk of Parkinson Disease Found in Rheumatoid Arthritis
Participants with rheumatoid arthritis had a 1.74-fold higher risk of PD compared with those without, raising importance of an elevated risk.
Details Behind Potential Phase 2 Trial With UB-312 Alpha Synuclein Vaccine for Parkinson Disease
Jean-Cosme Dodart, PhD, senior vice president of research at Vaxxinity, discussed the progress of the UB-312 Parkinson disease vaccine, highlighting its findings from a phase 1 clinical trial, and plans for a phase 2 trial.
Detecting Parkinson Disease at Early Stages With Alpha-Synuclein Amplification Assay: Russell Lebovitz, MD, PhD
The CEO and cofounder of Amprion spoke about additional diagnostic uses of the αSyn seed amplification assay and its validation in the Parkinson's Progression Markers Initiative study at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]
Visual Performance, Not Retinal Thickness, Better Indicator of Dementia Risk in Parkinson Disease
Poor higher order vision at baseline was associated with worsening cognition and increased probability of death, dementia, or frailty over 3 years.
Investigational Agent ALXN1840 Demonstrates Superior Efficacy to Standard of Care in Wilson Disease
Over 48 weeks of treatment, ALXN1480 was found to be generally well-tolerated, with improvements seen in Clinical Global Impression-Improvement scores and UWDRS Parts II and III.
Remaining Questions and Next Steps for Parkinson Agent P2B001: Lawrence Elmer, MD, PhD; Cheryl Fitzer-Attas, PhD
The medical director of the Center for Neurological Disorders at the University of Toledo discussed positive phase 3 findings assessing P2B001, and how the agent would potentially fit in the Parkinson treatment landscape. [WATCH TIME: 4 minutes]
Todd Levine, MD, on the Syn-One Test and Its Role in Neurodgenerative Disorder Diagnosis
The chief medical officer and cofounder of CND Life Sciences, who served as principal investigator of the study, offered insight into the Syn-ONe Test's clinical utility.
Oral Levodopa/Carbidopa Pump May Improve ON/OFF Time in Parkinson Disease
The pump, attached to a wearable retainer, continuously delivers the liquid medication with little to no adverse effects.
Syn-One Test Reports High Sensitivity and Specificity Across Multiple Synucleinopathies
CND Life Sciences’ α-synuclein skin biopsy test showed sensitivity rates ranging from 92.7% to 100% across a number of assessed and clinically confirmed synucleinopathies, including Parkinson disease and dementia with Lewy bodies, among others.
ND0162 Significantly Improves ON Time in Parkinson Disease in Phase 3 BouNDless Trial
Compared with immediate-release levodopa/carbidopa, NeuroDerm’s 24-hour subcutaneous liquid infusion improved ON time without dyskinesia and with nontroublesome dyskinesia.
Extended-Release Carbidopa/Levodopa Shows Tolerable Safety, Maintained Efficacy in Open-Label Extension
The majority of treatment-emergent adverse events from IPX203 were mild or moderate in nature, and occurred within the first 90 days of treatment.
Advances in Genetic Parkinson Disease With Alpha-Synuclein
Andrew Siderowf, MD, director of the Parkinson disease and movement center at the University of Pennsylvania, talked about available therapeutics and potential future therapies in research for Parkinson disease.
Promising Disease-Modifying Therapies in Parkinson Disease
Despite years of use of gold-standard therapy levodopa, therapeutic development in Parkinson disease has advanced rapidly and expanded to numerous novel pathways and targets.
NeuroVoices: Aaron Ritter, MD, on Navigating Treatment Options for Parkinson Disease Psychosis
The director of the Memory & Cognitive Disorders Clinic at Hoag Neuroscience Institute provided detail on an educational course that examined medication management for Parkinson disease psychosis.
Read All About It: How On-Demand Therapy Has Changed the PD Landscape
As therapeutic development has advanced in Parkinson disease management, the introduction of on-demand options have extended ON time for patients and altered the paradigm of care.
Managing Nonmotor Symptoms: Psychosis in Parkinson Disease
Psychosis is estimated to affect more than half of patients with Parkinson disease, and there is a growing need for improved management and therapeutic development.
Searching for the PD Holy Grail
The holy grail of neurodegenerative disorders would be to alter or halt the progression of the disease. For years, the discussion has swirled around stem cells and gene therapy, and they remain potential options for the future.
Race and Ethnicity Associated With Health-Related Quality of Life in Parkinson Disease
Findings from a recent published study observed lower quality of life in Black, Hispanic, and Asian patients with Parkinson disease compared with White patients.
Alpha-Synuclein Amplification Assay Aids Early Detection, With Potential to Improve Diagnosis and Treatment in Parkinson Disease
New research confirms a key disease pathology identified through examining spinal fluid in patients with Parkinson disease.
Evolving Role of Deep Brain Stimulation for Parkinson Disease, Essential Tremor: Julie Pilitsis, MD, PhD, MBA
The neurosurgeon at Marcus Neuroscience Institute, Baptist Health, provided perspective on the advances of DBS and other invasive procedures for patients with degenerative disorders. [WATCH TIME: 4 minutes]
Cerevance Announces Promising Data Updates on Innovative Approaches to Treating Parkinson Disease
Positive phase 2 data on CVN424, NETSseq platforms, and CVN417, a novel treatment for Parkinson disease, were presented at AD/PD 2023 International Conference.
Preclinical Data Demonstrates Potential of Small-Molecule Inhibitors of α-Synuclein Toxic Oligomers for Parkinson Disease
New data demonstrated the potential of a new class of oral, small molecule inhibitors that target the fleeting intermediates at the core of neurodegeneration in Parkinson disease.
Combination of Clenbuterol and Nadolol Formulations Show Positive Cognitive Impacts for Parkinson Disease
Statistically significant improvements in several quantitative test measures of episodic memory, attentiveness, and depressive emotional bias were observed in patients treated with clenbuterol and nadolol.
NeurologyLive® Brain Games: April 2, 2023
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Parkinson disease (PD).
Striking Differences in the Treatment of Parkinson Disease in the Last Decade
In honor of Parkinson Disease Awareness Month, Hubert Fernandez, MD, director of the Center for Neurological Restoration at Cleveland Clinic, provided perspective on the advances in the care for the neurodegenerative disorder.
Blarcamesine Deemed Safe, Effective in Phase 2 Extension Study of Parkinson Disease Dementia
Despite a pause in the trial due to the COVID-19 pandemic, patients who opted to continue treatment into the open-label extension demonstrated significant improvements in Parkinson disease dementia symptoms for up to 48 weeks.
SYMBYX Neuro Light Therapy Wellness Helmet Positively Impacts Parkinson Disease Symptoms
Over a 12-week treatment period, patients with Parkinson disease on light therapy demonstrated statistically significant improvements of 58% and 40% in lower and upper limb coordination and movement.
Reassessing Treatment Options, Quetiapine for Parkinson Disease Psychosis: Dilesh Doshi, PharmD
The vice president of Health Economic and Outcomes Research at Acadia Pharmaceuticals provided perspective on the negative effects seen from quetiapine and how the knowledge of pimavanserin has improved since approval. [WATCH TIME: 5 minutes]
FDA Issues Complete Response Letter for AbbVie’s 24-Hour Continuous Carbidopa/Levodopa Pump
If approved, ABBV-951 will become the first subcutaneous delivery of carbidopa/levodopa, often considered the standard of care for symptom management for patients with Parkinson disease.
Understanding the Reasons for Increased Mortality in Parkinson Disease Psychosis: Dilesh Doshi, PharmD
The vice president of Health Economic and Outcomes Research at Acadia Pharmaceuticals discussed the ongoing challenges with lowering mortality in Parkinson disease, and the need to improve caregiver burden. [WATCH TIME: 4 minutes]
Mechanistic Complications With Atypical Antipsychotics for Parkinson Disease Psychosis: Dilesh Doshi, PharmD
The vice president of Health Economics and Outcomes Research at Acadia Pharmaceuticals provided perspective on the mechanistic advantages of pimavanserin over atypical antipsychotics to treat Parkinson disease psychosis. [WATCH TIME: 2 minutes]
Physical Frailty Shows Association With Incident Parkinson Disease, Modified by Genetic Risk
Frailty domains such as exhaustion, slow gait speed, low grip strength, and low physical activity were all associated with incident Parkinson disease.
NeuroVoices: Justin Sporrer, MD, on Improvements and Benefits to High Intensity Focused Ultrasound in Essential Tremor
The director of functional neurosurgery at Baptist Health Miami Neuroscience Institute provided perspective on the growth of high intensity focused ultrasound and the lessons learned when treating essential tremor.
Cognitive and Functional Differences Identified in Parkinson Disease Prior to Diagnosis
Findings showed that global cognition declines in the prediagnostic period in men but not women with incident Parkinson disease, further indicating cognitive heterogeneity in the prodromal period by sex.
The Future of Genetic Approaches, New Targets in Parkinson Disease: James Beck, PhD
The senior vice president and chief scientific officer of the Parkinson’s Foundation discussed the potential for new therapies that target genetically mutated forms of Parkinson disease. [WATCH TIME: 3 minutes]
International Parkinson Disease Study Expands as PD GENEration Hits Recruitment Milestone
The international study on genetic testing and counseling, PD GENEration, is currently at the halfway mark of its goal of 15,000 participants.
Links Identified Between Cholinergic Nucleus 4 Degeneration, Isolated RBD, and Working Memory Impairments
Compared with healthy controls, those with isolated RBD performed significantly worse on all cognitive assessments except in tasks of executive function.
Reasons for the Increase in Parkinson Disease Incidence: James Beck, PhD
The senior vice president and chief scientific officer of the Parkinson’s Foundation detailed some of the potential reasons for the nearly 50% increase from the previously estimated rate. [WATCH TIME: 5 minutes]
Sex, Geographic Differences in the Incidence of Parkinson Disease: James Beck, PhD
The senior vice president and chief scientific officer of the Parkinson’s Foundation provided perspective on recently published findings showing a nearly doubling of Parkinson disease incidence that previously reported. [WATCH TIME: 4 minutes]
No Speech Changes Displayed After Early Neurostimulation in Parkinson Disease
Analysis on the EARLYSTIM trial assessing deep brain stimulation of the subthalamic nucleus in early Parkinson disease showed maintained speech intelligibility and nonspeech oral movements.
Higher Abdominis Thickness and Muscle Thickness Observed in Intolerable Abdominal Pain in Parkinson Disease
Investigators concluded that the therapeutic effectiveness of antiparkinsonian medications is short and limited for intolerable abdominal pain.
Pimavanserin and Clozapine Outperform Other Atypical Antipsychotics in Treating Parkinson Disease Psychosis
For controlling symptoms of Parkinson disease psychosis, pimavanserin had the most favorable effect size based on 2 major efficacy outcomes.
Greater Burden of Care Identified in Caregivers of Patients With Advanced Parkinson Disease
Caregivers of patients with advancing PD were more likely to spend more hours caring per day and had a higher self-perceived burden, compared with caregivers for patients with early PD.
Inspiring and Educating Young Medical Professionals to Parkinson Disease Care: Eli Pollard
The chief training and education officer at the Parkinson’s Foundation discussed the inclusion of various medical professionals that assist in Parkinson disease care, and the need to provide access to educational tools to inform clinicians. [WATCH TIME: 5 minutes]
REM-Sleep Behavior Disorder Associated With Worse Cognition in Subsequent Parkinson Disease
Nearly two-third of all participants with REM-sleep behavior disorder had mild cognitive impairment level 2 with multi-domain MCI, but particularly attention and memory deficits.
Episode 81: Widening the Therapeutic Window in Parkinson Disease
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Robert A. Hauser, MD, MBA. [LISTEN TIME: 20 minutes]
Cognitive Impairments in Activities of Daily Living Predict Conversion to Parkinson Disease Dementia
After a follow-up of nearly 4 years, nearly half of the patients (n = 10) with baseline classification of cognitive IADL impairment and mild cognitive impairment converted to dementia.
FDA Lifts Hold on Phase 2 Trial of Parkinson Agent IKT-148009
Going forward, the company must provide safety and steady-state pharmacokinetic data on the 200 mg dose of IKT-148009, as well as continued measurement of visual acuity and examination of the cornea and lens.
Mesdopetam Fails to Improve ON Time But Shows Anti-Dyskinesia Effects in Parkinson Disease
Mesdopetam showed significant effects on the secondary end point of Unified Dyskinesia Rating Scale, an assessment of involuntary movements associated with long-term treatment with dopaminergic medication.
Parkinson Disease Agent KM-819 Demonstrates Safe Profile in Phase 2 Study
KM-819, a potent inhibitor of FAF1, a key regulatory protein in cell death pathways, is currently being assessed in a 2-part trial, with results expected to help guide a future 24-month study.
Inconsistency Identified in Techniques Used to Assess Subjective Cognitive Complaints in Parkinson Disease
A systematic review revealed inconsistencies in the literature for assessing subjective cognitive complaints in cognitively normal patients with Parkinson disease.
Research Identifies Protective Drugs Toward Parkinson Disease, Warranting Future Consideration
Plain sulfonamide diuretics was identified as a drug chemical subgroup potentially inversely associated with Parkinson disease risk, while weaker signals included insulin and ß2-adrenergic agonists.
Systematic Study Identifies Association Between Incident Parkinson Disease and Antiepileptic Drug Use
Not previously explored, new findings showed links between antiseizure drug prescriptions and incident PD, with trends towards increased risk in those with greater number of prescription issues and multiple AEDs.
Clinical Outlook on ND0612 in Parkinson’s Disease
Ryan Case, PhD, head of clinical medical affairs at NeuroDerm, spoke about the main findings from the phase 3 BouNDless trial of ND0612 for Parkinson disease.
NeuroDerm’s 24-Hour Subcutaneous Levodopa Infusion Meets Primary End Point in Phase 3 BouNDless Study
In addition to improving ON time in patients with Parkinson disease, ND0612 was well tolerated, with only 6.3% of patients randomized to the treatment discontinuing the trial.
CSF Glucocerebrosidase Activity Associated With Risk of Dementia in Parkinson Disease
A population-based incident of Parkinson disease cases showed patients were more likely to develop PD dementia in 10 years with a lower level of lysosomal enzyme glucocerebrosidase activity.
Acupuncture Shows Effectiveness for Anxiety in Patients With Parkinson Disease
After 2 months of treatment, findings showed more improvement in anxiety and mental status with acupuncture in patients with Parkinson Disease than those on sham acupuncture.
Pimavanserin Lowers Mortality Better in Parkinson Disease Than Other Atypical Antipsychotics
Findings from a large-scale trial of adults aged 65 and older with Parkinson disease showed that treatment with pimavanserin was associated with lower risk of mortality than other atypical antipsychotics.
Timing of Orthostatic Hypotension, Not Symptom Severity, Increases Dementia Risk in Parkinson Disease, Multiple System Atrophy
The increased risk of dementia in patients showing early orthostatic hypotension was independent of the presence of concomitant supine hypertension and other factors associated with cognitive impairment.
Gait Dynamics Highly Associated With Autonomic Dysfunction in De Novo Parkinson Disease
Patients with high dysautonomia scores showed significantly slower walking speed, decreased cadence, and shorter stride but increased time than the lower scored group in backward gait.
Motor Symptoms Predate Prodromal Parkinson Disease by 3 Years, Study Finds
The case-control study identified numerous motor symptoms and signals that are associated with Parkinson disease diagnosis years after they begin to occur.
Range of Risk Factors, Comorbidities, and Prodromal Features Identified Prior to Parkinson Disease
Subsequent diagnosis of Parkinson disease was associated with a range of risk factors such as alcohol misuse and traumatic head injury, along with several other comorbidities and prodromal features.
Episode 78: A Virtual Reality Platform for Parkinson Disease
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jay Alberts, PhD. [LISTEN TIME: 27 minutes]
2 Clarke Drive Cranbury, NJ 08512